<VariationArchive VariationID="2427356" VariationName="NC_000019.9:g.(?_42471089)_(42486278_?)del" VariationType="Deletion" Accession="VCV002427356" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1950131" VariationID="2427356">
      <GeneList>
        <Gene Symbol="ATP1A3" FullName="ATPase Na+/K+ transporting subunit alpha 3" GeneID="478" HGNC_ID="HGNC:801" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="41966582" stop="41994230" display_start="41966582" display_stop="41994230" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="42470733" stop="42498427" display_start="42470733" display_stop="42498427" Strand="-" />
          </Location>
          <OMIM>182350</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000019.9:g.(?_42471089)_(42486278_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" innerStart="42471089" innerStop="42486278" display_start="42471089" display_stop="42486278" variantLength="15190" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.(?_42471089)_(42486278_?)del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.(?_42471089)_(42486278_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000019.9:g.(?_42471089)_(42486278_?)del AND Dystonia 12" Accession="RCV003113685" Version="4">
        <ClassifiedConditionList TraitSetID="3518">
          <ClassifiedCondition DB="MedGen" ID="C1868681">Dystonia 12</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-11-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-11-17" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">30283815</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3518" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1998" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">DYT-ATP1A3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Dystonia 12</ElementValue>
                <XRef ID="MONDO:0007496" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rapid-Onset Dystonia-Parkinsonism</ElementValue>
                <XRef ID="NBK1115" DB="GeneReviews" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">DYT12</ElementValue>
                <XRef Type="MIM" ID="128235" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RDP</ElementValue>
                <XRef Type="MIM" ID="128235" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">ATP1A3-related neurologic disorders represent a clinical continuum in which at least three distinct phenotypes have been delineated: rapid-onset dystonia-parkinsonism (RDP); alternating hemiplegia of childhood (ACH); and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS). However, some affected individuals have intermediate phenotypes or only a few features that do not fit well into one of these major phenotypes. RDP has been characterized by: abrupt onset of dystonia over days to weeks with parkinsonism (primarily bradykinesia and postural instability); common bulbar involvement; and absence or minimal response to an adequate trial of L-dopa therapy, with few exceptions. Often fever, physiologic stress, or alcoholic binges trigger the onset of symptoms. After their initial appearance, symptoms often stabilize with little improvement; occasionally second episodes occur with abrupt worsening of symptoms. Rarely, affected individuals have reported a more gradual onset of symptoms over weeks to months. Anxiety, depression, and seizures have been reported. Age of onset ranges from four to 55 years, although a childhood variation of RDP with onset between ages nine and 14 months has been reported. AHC is a complex neurodevelopmental syndrome most frequently manifesting in infancy or early childhood with paroxysmal episodic neurologic dysfunction including alternating hemiparesis or dystonia, quadriparesis, seizure-like episodes, and oculomotor abnormalities. Episodes can last for minutes, hours, days, or even weeks. Remission of symptoms occurs with sleep and immediately after awakening. Over time, persistent neurologic deficits including oculomotor apraxia, ataxia, choreoathetosis, dystonia, parkinsonism, and cognitive and behavioral dysfunction develop in the majority of those affected; more than 50% develop epilepsy in addition to their episodic movement disorder phenotype. CAPOS (cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss) syndrome is characterized by episodes of ataxic encephalopathy and/or weakness during and after a febrile illness. Onset is between ages six months and four years. Some acute symptoms resolve; progression of sensory losses and severity vary.</Attribute>
                <XRef ID="NBK1115" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">ATP1A3-Related Neurologic Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9628" />
                <XRef ID="9628" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301294</ID>
                <ID Source="BookShelf">NBK1115</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301334</ID>
                <ID Source="BookShelf">NBK1155</ID>
              </Citation>
              <XRef ID="71517" DB="Orphanet" />
              <XRef ID="C1868681" DB="MedGen" />
              <XRef ID="MONDO:0007496" DB="MONDO" />
              <XRef Type="MIM" ID="128235" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7076359" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_152296.4_19_Deletion (exons 9-23)|MedGen:C1868681" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003796429" DateUpdated="2024-06-09" DateCreated="2023-02-13" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-11-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">30283815</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the ATP1A3 protein in which other variant(s) (p.Gly947Glu) have been determined to be pathogenic (PMID: 30283815). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with ATP1A3-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 9-23 of the ATP1A3 gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATP1A3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.(?_42471089)_(42486278_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1868681" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7076359" TraitType="Disease" MappingType="XRef" MappingValue="C1868681" MappingRef="MedGen">
        <MedGen CUI="C1868681" Name="Dystonia 12" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

